• Asian Pacific Journal of Cancer Prevention
• /
• 제15권9호
• /
• pp.3927-3932
• /
• 2014

Background: Epidermal growth factor receptor (EGFR) mutations and echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) define specific molecular subsets of lung adenocarcinomas with distinct clinical features. Our purpose was to analyze clinical features and prognostic value of EGFR gene mutations and the EML4-ALK fusion gene in lung adenocarcinoma. Patients and Methods: EGFR gene mutations and the EML4-ALK fusion gene were detected in 92 lung adenocarcinoma patients in China. Tumor marker levels before first treatment were measured by electrochemiluminescence immunoassay. Results: EGFR mutations were found in 40.2% (37/92) of lung adenocarcinoma patients, being identified at high frequencies in never-smokers (48.3% vs. 26.5% in smokers; P=0.040) and in patients with abnormal serum carcinoembryonic antigen (CEA) levels before the initial treatment (58.3% vs. 28.6%, P=0.004). Multivariate analysis revealed that a higher serum CEA level before the initial treatment was independently associated with EGFR gene mutations (95%CI: 1.476~11.343, P=0.007). We also identified 8 patients who harbored the EML4-ALK fusion gene (8.7%, 8/92). In concordance with previous reports, younger age was a clinical feature for these (P=0.008). Seven of the positive cases were never smokers, and no coexistence with EGFR mutation was discovered. In addition, the frequency of the EML4-ALK fusion gene among patients with a serum CEA concentration below 5ng/ml seemed to be higher than patients with a concentration over 5ng/ml (P=0.021). No significant difference was observed for time to progression and overall survival between EML4-ALK-positive group and EML4-ALK-negative group or between patients with and without an EGFR mutation. Conclusions: The serum CEA level before the initial treatment may be helpful in screening population for EGFR mutations or EML4-ALK fusion gene presence in lung adenocarcinoma patients.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권15호
• /
• pp.6569-6573
• /
• 2015

Objective: To evaluate the application value of serum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis of pancreatic cancer cases treated with concurrent chemotherapy. Materials and Methods: 52 patients with pancreatic cancer, 40 with benign pancreatic diseases and 40 healthy people were selected. The electrochemiluminescence immunoassay method was used for detecting levels of CA19-9, CEA and CA125, and a CanAg CA242 enzyme linked immunoassay kit for assessing the level of CA242. The Kaplan-Meier method was used for analyzing the prognostic factors of patients with pancreatic cancer. The Cox proportional hazard model was applied for analyzing the hazard ratio (HR) and 95% confidential interval (CI) for survival time of patients with pancreatic cancer. Results: The levels of serum CA19-9, CEA, CA125 and CA242 in patients with pancreatic cancer were significantly higher than those in patients with benign pancreatic diseases and healthy people (P<0.001). The sensitivity of CA19-9 was the highest among these, followed by CA242, CA125 and CEA. The specificity of CA242 is the highest, followed by CA125, CEA and CA19-9. The sensitivity and specificity of joint detection of serum CA19-9, CEA, CA125and CA242 were 90.4% and 93.8%, obviously higher than single detection of those markers in diagnosis of pancreatic cancer. The median survival time of 52 patients with pancreatic cancer was 10 months (95% CI7.389~12.611).. Patients with the increasing level of serum CA19-9, CEA, CA125, CA242 had shorter survival times (P=0.047. 0.043, 0.0041, 0.029). COX regression analysis showed that CA19-9 was an independent prognostic factor for patients with pancreatic cancer (P=0.001, 95%CI 2.591~38.243). Conclusions: The detection of serum tumor markers (CA19.9, CEA, CA125 and CA242) is conducive to the early diagnosis of pancreatic cancer and joint detection of tumor markers helps improve the diagnostic efficiency. Moreover, CA19-9 is an independent prognostic factor for patients with pancreatic cancer.

• Tuberculosis and Respiratory Diseases
• /
• 제56권1호
• /
• pp.67-76
• /
• 2004

연구배경 : 만성호흡기질환 환자에서 폐동맥고혈압은 불량한 예후를 나타낸다. 접근성이 용이하고 비침습적인 방법으로서 혈청 NT-proBNP농도 측정이 폐동맥고혈압 진단에 유용성이 있는지 알아보기 위하여 본 연구를 진행하였다. 방 법 : 임상적으로 수축기 폐동맥고혈압이 의심되는 환자 29명을 대상으로 전기화학발광 면역분석법을 이용하여 혈청 NT-proBNP농도를 측정하였고, 동맥혈가스검사, 혈청 생화학검사, 폐기능검사, 그리고 도플러 심초음파검사를 실시하여 우심실 수축기압을 통해 수축기 폐동맥압을 예측하였다. 결 과 : 로그 값으로 치환한 혈청 NT-proBNP농도와 수축기 폐동맥압과는 양성 선형 상관관계를 갖고 있었다(Correlation coefficiency: 0.783, p-value < 0.001). 혈청 NT-proBNP 농도는 우심실 수축기압, 우심실 비대, 심실간 중격의 편평화, 우심실 확장과 유의한 관련이 있었다. 결 론 : 임상적으로 폐동맥고혈압을 의심하는 환자에서 혈청 NT-proBNP 농도 측정은 간단하게 폐동맥고혈압 유무를 알 수 있는 유용한 표지자로서 사용이 가능할 것으로 보이며, 이에 대한 추가 연구가 필요하리라 생각된다.

• Laboratory Medicine and Quality Assurance
• /
• 제40권2호
• /
• pp.51-69
• /
• 2018

대한임상검사정도관리협회 면역혈청프로그램의 2016년 간염바이러스 항원항체검사 신빙도조사 사업은 6월과 10월에, 2017년 신빙도조사사업은 5월과 10월에 2회에 걸쳐 시행되었다. 간염바이러스 항원항체검사 신빙도조사사업은 총 10종목에 대하여 실시하였다. 저자들은 2016년 1회차 2개, 2회차 3개의 혼합혈청 검체를 각각 965기관, 962기관에 발송하였다. 참여기관은 1회차에 915 기관(94.8%), 2회차 913기관(95.0%)이었다. 2017년도에는 매 회차 3개의 혼주혈청 검체를 각각 936기관, 1,015기관에 발송하였다. 참여기관은 1회차에 920기관(98.3%), 2회차 996기관(98.1%) 이었다. Hepatitis B surface antigen에 가장 많은 기관이 참여하였고, hepatitis B surface antigen, anti-hepatitis C virus, hepatitis B envelope antigen, antibodies to hepatitis B envelope antigen, anti-hepatitis A virus 및 antibodies to hepatitis B core antigen 순으로 참여하였다. 간염바이러스 항원항체검사 신빙도조사 결과, matrix effect로 인하여 전기화학발광면역검사법을 포함한 화학발광면역검사법에서 위양성 결과가 발생하였다. Anti-hepatitis A virus검사에서 면역크로마토그래피법의 낮은 민감도는 위음성 결과를 초래하였다. 검사실의 간염바이러스 신빙도조사사업의 지속적인 참여를 통한 검사의 질 향상이 필요할 것으로 생각되었다.